What changed in this filing

/stocks — the workspaceLOADING

Item 1. Business

2024-04-01 compared with 2023-03-31 · 37 added, 47 removed, 191 unchanged (31% of the section changed)

34 unchanged sentences

The Company’s principal operations coincide with those of NewStem.

We have not received any dividend payments or other distributions from NewStem in the fiscal years ended December 31, 2022 and 2021.

We received distributions of earnings from NetCo of $12,591 and $21,290, respectively, for the fiscal years ended December 31, 2022 and

is a development stage Israeli biotech limited liability company focused on human Pluripotent Stem Cells (hPSCs) in general, and Haploid

human Pluripotent Stem Cells (HhPSCs), in particular.

These cells have the potential to change the face of medical research as they play

a pivotal role in cancer research, regenerative medicine and disease therapy.

NewStem established a discovery bio-platform based on haploid

human embryonic stem cell technology for genome-wide screenings and is currently using this platform for the discovery and development

of oncology drugs based on synthetic lethal interaction and developing a personalized diagnostic for early detection of chemotherapy

NewStem has incurred losses since inception and has not generated any revenues to date.

NewStem filed an FDA Pre-Submission

and received a CE Mark from the European Medicines Agency (EMA) for its in vitro diagnostic device (IVDD).

NewStem does not have an FDA

approved medical device.

The NewStem Software Diagnostic Device (NSDD) is CE marked under EU regulation as an “other” IVD

under Directive 98/79/EC since March 2022.

We have not received any dividend

payments or other distributions from NewStem in the fiscal years ended December 31, 2023 and 2022.

We received distributions of earnings

from NetCo of $6,875 and $12,591, respectively, for the fiscal years ended December 31, 2023 and 2022.

is a development stage Israeli biotech limited liability company focused on human Pluripotent Stem Cells (hPSCs) in general, and

Haploid human Pluripotent Stem Cells (HhPSCs), in particular.

These cells have the potential to change the face of medical research

as they play a pivotal role in cancer research, regenerative medicine and disease therapy.

NewStem established a discovery

bio-platform based on haploid human embryonic stem cell technology for genome-wide screenings and is currently using this platform

for the discovery and development of oncology drugs based on synthetic lethal interaction and developing a personalized diagnostic

for early detection of chemotherapy resistance.

NewStem has incurred losses since inception and has generated minimal revenues from

a licensing agreement to date.

NewStem filed an FDA Pre-Submission and received a CE Mark from the European Medicines Agency (EMA)

for its in vitro diagnostic device (IVDD).

NewStem does not have an FDA approved medical device.

The NewStem Software Diagnostic

Device (NSDD) is CE marked under EU regulation as an “other” IVD under Directive 98/79/EC since March 2022.

performs genome-wide genetic screening to identify synthetic lethal interactions with common cancer-related mutations.

13 unchanged sentences

The validation process

requires additional experiments that corroborate the results in independent experiments that corroborate the results in independent experiments

requires additional experiments that corroborate the results in independent experiments

that are performed on haploid human embryonic stem cells and cancer models.

95 unchanged sentences

will be subjected to a retrospective pivotal clinical testing that will be followed by the de novo submission to the FDA.

has a collaboration with Memorial Sloan Kettering Cancer Center (“MSK”) Innovation Hub to further optimize and validate NewStem’s

bioinformatics-based software as a medical device diagnostic platform.

The NewStem Software Diagnostic Device (“NSDD”) provides

information to oncologists regarding the presence of mutations in a patient’s tumor profile which may confer resistance to certain

anti-cancer drugs.

Armed with NSDD-based intelligence, oncologists can make more informed treatment decisions.

The collaboration is focused

on triple-negative breast cancer patients and non-small cell lung cancer patients treated with Paclitaxel and/or Carboplatin.

expects to receive genomic data from the MSK Innovation Hub within the next few months.

That data will be analyzed and compared to the

data that the NSDD generates for that particular patient.

MSK Innovation Hub brings together innovative, digitally focused companies with MSK’s community of researchers, clinicians, and

digital health professionals through a program designed to establish innovative collaborations that can have a tangible impact on treatment

or management of cancer.

Regulatory Requirements

20 unchanged sentences

Group”), formed the joint venture, NetCo.

NetCo owns the entertainment

property, “Net Force”, about a division of the FBI investigating crimes and adventures involving the internet and the digital

NetCo owns the entertainment property,

“Net Force”, about a division of the FBI investigating crimes and adventures involving the internet and the digital world.

Group each own 50% of the ownership interest in NetCo.

NetCo owns all rights in all media to the Net Force

property including film, television, and video games.

1997, NetCo licensed to Putnam Berkley the rights to publish the first six Net Force books in North America, which books were

written and published.

NetCo owns all rights in all media to the Net Force property including

film, television, and video games.

1997, NetCo licensed to Putnam Berkley the rights to publish the first six Net Force books in North America, which books were written

and published.

This agreement was subsequently renewed in December 2001 for four more books that were created and published.

There was also a series of books targeted to the young adult market, Net Force Explorer, also published by Putnam Berkley.

books have so far been published in mass market paperback format.

The first book in the series was adapted as a four-hour mini-series

on the ABC television network.

also a series of books targeted to the young adult market, Net Force Explorer, also published by Putnam Berkley.

Net Force books have

so far been published in mass market paperback format.

The first book in the series was adapted as a four-hour mini-series on the ABC

television network.

2019, NetCo entered into a new publishing agreement with HarperCollins.

Three novels and two Net Force novellas have been published

under that agreement.

Through its interest in NetCo, NovelStem receives distributions of its 50% share of proceeds generated

from the rights to Net Force.

Three novels and two Net Force novellas have been published under

that agreement.

Through its interest in NetCo, NovelStem receives distributions of its 50% share of proceeds generated from the rights

to Net Force.

in the publishing and video game industries is intense.

2 unchanged sentences

total revenue in each segment.

NetCo’s competitors range from established interactive entertainment companies and diversified

media companies to emerging start-ups, and we expect new competitors to continue to emerge throughout the world.

NetCo’s competitors range from established interactive entertainment companies and diversified media

companies to emerging start-ups, and we expect new competitors to continue to emerge throughout the world.

Item 3 – Legal Proceedings for information concerning proceedings related to NetCo.

14 unchanged sentences

Compared sentence by sentence after normalising whitespace, quotation marks, case and digits, so re-formatting and restated figures do not read as changed language. Wording changes appear as one removal and one addition. The current filing and the prior one are authoritative.

What changed 10-K

Item 1. Business